Rational repurposing, synthesis, in vitro and in silico studies of chromone-peptidyl hybrids as potential agents against Leishmania donovani

References

• Joshi G, Quadir SS, Yadav KS. Road map to the treatment of neglected tropical diseases: nanocarriers interventions. J Control Release. 2021;339:51–74.
   PubMed Web of Science ®Google Scholar
• Bilgic-Temel A, Murrell DF, Uzun S. Cutaneous leishmaniasis: a neglected disfiguring disease for women. Int J Womens Dermatol. 2019;5(3):158–165.
   PubMedGoogle Scholar
• Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, Jannin J, Boer Md. Leishmaniasis Worldwide and Global Estimates of Its Incidence. PLoS One. 2012;7(5):e35671.
   PubMed Web of Science ®Google Scholar
• Tuon FF, Dantas LR, de Souza RM, Ribeiro VST, Amato VS. Liposomal drug delivery systems for the treatment of leishmaniasis. Parasitol Res. 2022;121(11):3073–3082.
   PubMed Web of Science ®Google Scholar
• Pinheiro AC, de Souza MVN. Current leishmaniasis drug discovery. RSC Med Chem. 2022;13(9):1029–1043.
   PubMedGoogle Scholar
• Madusanka RK, Silva H, Karunaweera ND. Treatment of Cutaneous Leishmaniasis and insights into species-specific responses: a narrative review. Infect Dis Ther. 2022;11(2):695–711.
   PubMed Web of Science ®Google Scholar
• de Santana NS, de Oliveira de Siqueira LB, Santos-Oliveira R, dos Santos Matos AP, Ricci-Júnior E. Nanoparticles for the treatment of visceral leishmaniasis: review. J Nanoparticle Res. 2023;25:24.
   Web of Science ®Google Scholar
• Khabsa J, Jain S, El-Harakeh A, Rizkallah C, Pandey DK, Manaye N, Honein-AbouHaidar G, Halleux C, Dagne DA, Akl EA. Stakeholders’ views and perspectives on treatments of visceral leishmaniasis and their outcomes in HIV-coinfected patients in East Africa and South-East Asia: a mixed methods study. PLoS Negl Trop Dis. 2022;16(8):e0010624.
   PubMed Web of Science ®Google Scholar
• Kumari S, Kumar V, Tiwari RK, Ravidas V, Pandey K, Kumar A. Amphotericin B: a drug of choice for Visceral Leishmaniasis. Acta Trop. 2022;235:106661.
   PubMed Web of Science ®Google Scholar
• Yeshaw Y, Tsegaye AT, Nigatu SG. Incidence of mortality and its predictors among adult Visceral Leishmaniasis patients at the university of Gondar hospital: a retrospective cohort study. Infect Drug Resist. 2020;13:881–891.
   PubMed Web of Science ®Google Scholar
• Scarpini S, Dondi A, Totaro C, Biagi C, Melchionda F, Zama D, Pierantoni L, Gennari M, Campagna C, Prete A, et al. Visceral Leishmaniasis: epidemiology, diagnosis, and treatment regimens in different geographical areas with a focus on pediatrics. Microorganisms. 2022;10(10):1887.
   PubMed Web of Science ®Google Scholar
• Wijnant G-J, Dumetz F, Dirkx L, Bulté D, Cuypers B, Van Bocxlaer K, Hendrickx S. Tackling drug resistance and other causes of treatment failure in Leishmaniasis. Front Trop Dis. 2022;3:837460.
   Google Scholar
• Jourdan J-P, Bureau R, Rochais C, Dallemagne P. Drug repositioning: a brief overview. J Pharm Pharmacol. 2020;72(9):1145–1151.
   PubMed Web of Science ®Google Scholar
• Hassan AHE, Phan T-N, Choi Y, Moon S, No JH, Lee YS. Design, rational repurposing, synthesis, in vitro evaluation, homology modeling and in silico study of Sulfuretin Analogs as Potential Antileishmanial hit compounds. Pharmaceuticals. 2022;15(9):1058.
   Web of Science ®Google Scholar
• Farag AK, Hassan AHE, Ahn BS, Park KD, Roh EJ. Reprofiling of pyrimidine-based DAPK1/CSF1R dual inhibitors: identification of 2,5-diamino-4-pyrimidinol derivatives as novel potential anticancer lead compounds. J Enzyme Inhib Med Chem. 2020;35(1):311–324.
   PubMed Web of Science ®Google Scholar
• Braga SS. Multi-target drugs active against leishmaniasis: a paradigm of drug repurposing. Eur J Med Chem. 2019;183:111660.
   PubMed Web of Science ®Google Scholar
• Rai P, Arya H, Saha S, Kumar D, Bhatt TK. Drug repurposing based novel anti-leishmanial drug screening using in-silico and in-vitro approaches. J Biomol Struct Dyn. 2022;40(21):10812–10820.
   PubMed Web of Science ®Google Scholar
• Tabrez S, Rahman F, Ali R, Muhammad F, Alshehri BM, Alaidarous MA, Banawas S, Dukhyil AAB, Rub A. Repurposing of FDA-approved drugs as inhibitors of sterol C-24 methyltransferase of Leishmania donovani to fight against leishmaniasis. Drug Dev Res. 2021;82(8):1154–1161.
   PubMed Web of Science ®Google Scholar
• Farag AK, Hassan AHE, Chung K-S, Lee J-H, Gil H-S, Lee K-T, Roh EJ. Diarylurea derivatives comprising 2,4-diarylpyrimidines: discovery of novel potential anticancer agents via combined failed-ligands repurposing and molecular hybridization approaches. Bioorg Chem. 2020;103:104121.
   PubMed Web of Science ®Google Scholar
• Hassan AHE, Yoo SY, Lee KW, Yoon YM, Ryu HW, Jeong Y, Shin J-S, Kang S-Y, Kim S-Y, Lee H-H, et al. Repurposing mosloflavone/5,6,7-trimethoxyflavone-resveratrol hybrids: discovery of novel p38-α MAPK inhibitors as potent interceptors of macrophage-dependent production of proinflammatory mediators. Eur J Med Chem. 2019;180:253–267.
   PubMed Web of Science ®Google Scholar
• Berenstein AJ, Magariños MP, Chernomoretz A, Agüero F. A multilayer network approach for guiding drug repositioning in neglected diseases. PLoS Negl Trop Dis. 2016;10(1):e0004300.
   PubMed Web of Science ®Google Scholar
• Andrade-Neto VV, Cunha-Junior EF, Faioes VdS, Martins TP, Silva RL, Leon LL, Torres-Santos EC. Leishmaniasis treatment: update of possibilities for drug repurposing. Front Biosci. 2018;23:967–996.
   PubMed Web of Science ®Google Scholar
• Cutinho PF, Shankar RC, Anand A, Roy J, Mehta CH, Nayak UY, Murahari M. Hit identification and drug repositioning of potential non-nucleoside reverse transcriptase inhibitors by structure-based approach using computational tools (part II). J Biomol Struct Dyn. 2020;38(13):3772–3789.
   PubMed Web of Science ®Google Scholar
• Ferreira Letícia T, Rodrigues J, Cassiano Gustavo C, Tavella Tatyana A, Tomaz Kaira Cristina P, Baia-da-Silva Djane C, Souza Macejane F, Lima Marilia Nunes do N, Mottin M, Almeida Ludimila D, et al. Computational chemogenomics drug repositioning strategy enables the discovery of epirubicin as a new repurposed hit for Plasmodium falciparum and P. vivax. Antimicrob Agents Chemother. 2020;64(9):e02041-02019.
   Web of Science ®Google Scholar
• Casanova M, Gonzalez IJ, Sprissler C, Zalila H, Dacher M, Basmaciyan L, Späth GF, Azas N, Fasel N. Implication of different domains of the Leishmania major metacaspase in cell death and autophagy. Cell Death Dis. 2015;6(10):e1933.
   PubMedGoogle Scholar
• d’Avila-Levy CM, Marinho FA, Santos LO, Martins JL, Santos ALS, Branquinha MH. Antileishmanial activity of MDL 28170, a potent calpain inhibitor. Int J Antimicrob Agents. 2006;28(2):138–142.
   PubMed Web of Science ®Google Scholar
• Marinho FA, Gonçalves KCS, Oliveira SSC, Gonçalves DS, Matteoli FP, Seabra SH, Oliveira ACS, Bellio M, Oliveira SS, Souto-Padrón T, et al. The Calpain Inhibitor MDL28170 induces the expression of apoptotic markers in Leishmania amazonensis Promastigotes. PLoS One. 2014;9(1):e87659.
   PubMed Web of Science ®Google Scholar
• Steert K, Berg M, Mottram JC, Westrop GD, Coombs GH, Cos P, Maes L, Joossens J, Van der Veken P, Haemers A, et al. α-Ketoheterocycles as inhibitors of Leishmania mexicana Cysteine protease CPB. ChemMedChem. 2010;5(10):1734–1748.
   PubMed Web of Science ®Google Scholar
• Marinho FA, Sangenito LS, Oliveira SSC, De Arruda LB, D'Ávila-Levy CM, Santos ALS, Branquinha MH. The potent cell permeable calpain inhibitor MDL28170 affects the interaction of Leishmania amazonensis with macrophages and shows anti-amastigote activity. Parasitol Int. 2017;66(5):579–583.
   PubMed Web of Science ®Google Scholar
• Ennes-Vidal V, Menna-Barreto RFS, Branquinha MH, Dos Santos ALS, D'Avila-Levy CM. Why calpain inhibitors are interesting leading compounds to search for new therapeutic options to treat leishmaniasis? Parasitology. 2017;144(2):117–123.
   PubMed Web of Science ®Google Scholar
• Hassan AHE, Kim HJ, Park K, Choi Y, Moon S, Lee CH, Kim YJ, Cho SB, Gee MS, Lee D, et al. Synthesis and biological evaluation of O6-Aminoalkyl-Hispidol analogs as multifunctional monoamine oxidase-B inhibitors towards management of neurodegenerative diseases. Antioxidants. 2023;12(5):1033.
   Web of Science ®Google Scholar
• Lee H-H, Shin J-S, Chung K-S, Kim J-M, Jung S-H, Yoo H-S, Hassan AHE, Lee JK, Inn K-S, Lee S, et al. 3′,4′-Dihydroxyflavone mitigates inflammatory responses by inhibiting LPS and TLR4/MD2 interaction. Phytomedicine. 2023;109:154553.
   PubMed Web of Science ®Google Scholar
• Hassan AHE, Kim HJ, Gee MS, Park J-H, Jeon HR, Lee CJ, Choi Y, Moon S, Lee D, Lee JK, et al. Positional scanning of natural product hispidol’s ring-B: discovery of highly selective human monoamine oxidase-B inhibitor analogues downregulating neuroinflammation for management of neurodegenerative diseases. J Enzyme Inhib Med Chem. 2022;37(1):768–780.
   PubMed Web of Science ®Google Scholar
• Gil H-S, Lee J-H, Farag AK, Hassan AHE, Chung K-S, Choi J-H, Roh E-J, Lee K-T. AKF-D52, a synthetic Phenoxypyrimidine-urea derivative, triggers extrinsic/intrinsic apoptosis and cytoprotective autophagy in human non-small cell lung cancer cells. Cancers. 2021;13(22):5849.
   PubMed Web of Science ®Google Scholar
• Forman HJ, Zhang H. Targeting oxidative stress in disease: promise and limitations of antioxidant therapy. Nat Rev Drug Discov. 2021;20(9):689–709.
   PubMed Web of Science ®Google Scholar
• Miranda-Sapla MM, Tomiotto-Pellissier F, Assolini JP, Carloto ACM, Bortoleti BTdS, Gonçalves MD, Tavares ER, Rodrigues JHdS, Simão ANC, Yamauchi LM, et al. trans-Chalcone modulates Leishmania amazonensis infection in vitro by Nrf2 overexpression affecting iron availability. Eur J Pharmacol. 2019;853:275–288.
   PubMed Web of Science ®Google Scholar
• Tomiotto-Pellissier F, Alves DR, Miranda-Sapla MM, de Morais SM, Assolini JP, da Silva Bortoleti BT, Gonçalves MD, Cataneo AHD, Kian D, Madeira TB, et al. Caryocar coriaceum extracts exert leishmanicidal effect acting in promastigote forms by apoptosis-like mechanism and intracellular amastigotes by Nrf2/HO-1/ferritin dependent response and iron depletion: Leishmanicidal effect of Caryocar coriaceum leaf exracts. Biomed Pharmacother. 2018;98:662–672.
   PubMed Web of Science ®Google Scholar
• Cataneo AHD, Tomiotto-Pellissier F, Miranda-Sapla MM, Assolini JP, Panis C, Kian D, Yamauchi LM, Colado Simão AN, Casagrande R, Pinge-Filho P, et al. Quercetin promotes antipromastigote effect by increasing the ROS production and anti-amastigote by upregulating Nrf2/HO-1 expression, affecting iron availability. Biomed Pharmacother. 2019;113:108745.
   PubMed Web of Science ®Google Scholar
• Kim SH, Lee YH, Jung SY, Kim HJ, Jin C, Lee YS. Synthesis of chromone carboxamide derivatives with antioxidative and calpain inhibitory properties. Eur J Med Chem. 2011;46(5):1721–1728.
   PubMed Web of Science ®Google Scholar
• Hassan AHE, Phan T-N, Yoon S, Lee CJ, Jeon HR, Kim S-H, No JH, Lee YS. Pyrrolidine-based 3-deoxysphingosylphosphorylcholine analogs as possible candidates against neglected tropical diseases (NTDs): identification of hit compounds towards development of potential treatment of Leishmania donovani. J Enzyme Inhib Med Chem. 2021;36(1):1922–1930.
   PubMed Web of Science ®Google Scholar
• Phan T-N, Baek K-H, Lee N, Byun SY, Shum D, No JH. In vitro and in vivo activity of mTOR kinase and PI3K inhibitors Against Leishmania donovani and Trypanosoma brucei. Molecules. 2020;25(8):1980.
   PubMed Web of Science ®Google Scholar
• Silva CFM, Pinto DCGA, Fernandes PA, Silva AMS. Evolution of chromone-like compounds as potential antileishmanial agents, through the 21st century. Expert Opin Drug Discov. 2020;15(12):1425–1439.
   PubMed Web of Science ®Google Scholar
• Cardona-Galeano W, Yepes AF, Quintero-Saumeth J, Robledo SM, Alzate F, Rojano B. A biologically active chromone from Bomarea setacea (alstroemeriaceae): Leishmanicidal, antioxidant and multilevel computational studies. ChemistrySelect. 2022;7(45):e202203852.
   Web of Science ®Google Scholar
• Mallick S, Dutta A, Ghosh J, Maiti S, Mandal AK, Banerjee R, Bandyopadhyay C, Pal C. protective therapy with Novel chromone derivative against Leishmania donovani infection induces Th1 response in vivo. Chemotherapy. 2011;57(5):388–393.
   PubMed Web of Science ®Google Scholar
• Otero E, Vergara S, Robledo SM, Cardona W, Carda M, Vélez ID, Rojas C, Otálvaro F. Synthesis, Leishmanicidal and cytotoxic activity of Triclosan-Chalcone, Triclosan-chromone and Triclosan-coumarin hybrids. Molecules. 2014;19(9):13251–13266.
   PubMed Web of Science ®Google Scholar
• Coa JC, García E, Carda M, Agut R, Vélez ID, Muñoz JA, Yepes LM, Robledo SM, Cardona WI. Synthesis, leishmanicidal, trypanocidal and cytotoxic activities of quinoline-chalcone and quinoline-chromone hybrids. Med Chem Res. 2017;26(7):1405–1414.
   Web of Science ®Google Scholar
• Kim S-Y, Hassan AHE, Chung K-S, Kim S-Y, Han H-S, Lee H-H, Jung S-H, Lee K-Y, Shin J-S, Jang E, et al. Mosloflavone-resveratrol hybrid TMS-HDMF-5z exhibits potent in vitro and in vivo anti-inflammatory effects through NF-κB, AP-1, and JAK/STAT inactivation. Front Pharmacol. 2022;13:857789.
   PubMed Web of Science ®Google Scholar
• Hong JY, Chung K-S, Shin J-S, Lee J-H, Gil H-S, Lee H-H, Choi E, Choi J-H, Hassan AHE, Lee YS, et al. The anti-proliferative activity of the Hybrid TMS-TMF-4f compound against human cervical cancer involves apoptosis mediated by STAT3 inactivation. Cancers. 2019;11(12):1927.
   PubMed Web of Science ®Google Scholar
• Hassan AHE, Choi E, Yoon YM, Lee KW, Yoo SY, Cho MC, Yang JS, Kim HI, Hong JY, Shin J-S, et al. Natural products hybrids: 3,5,4′-Trimethoxystilbene-5,6,7-trimethoxyflavone chimeric analogs as potential cytotoxic agents against diverse human cancer cells. Eur J Med Chem. 2019;161:559–580.
   PubMed Web of Science ®Google Scholar
• Alam MM, Hassan AHE, Lee KW, Cho MC, Yang JS, Song J, Min KH, Hong J, Kim D-H, Lee YS. Design, synthesis and cytotoxicity of chimeric erlotinib-alkylphospholipid hybrids. Bioorg Chem. 2019;84:51–62.
   PubMed Web of Science ®Google Scholar
• Alam MM, Hassan AHE, Kwon YH, Lee HJ, Kim NY, Min KH, Lee S-Y, Kim D-H, Lee YS. Design, synthesis and evaluation of alkylphosphocholine-gefitinib conjugates as multitarget anticancer agents. Arch Pharm Res. 2018;41(1):35–45.
   PubMed Web of Science ®Google Scholar
• Lee KY, Seob Lee K, Jin C, Lee YS. Design and synthesis of calpain inhibitory 6-pyridone 2-carboxamide derivatives. Eur J Med Chem. 2009;44(3):1331–1334.
   PubMed Web of Science ®Google Scholar
• Kulshrestha A, Bhandari V, Mukhopadhyay R, Ramesh V, Sundar S, Maes L, Dujardin JC, Roy S, Salotra P. Validation of a simple resazurin-based promastigote assay for the routine monitoring of miltefosine susceptibility in clinical isolates of Leishmania donovani. Parasitol Res. 2013;112(2):825–828.
   PubMed Web of Science ®Google Scholar
• Branquinha MH, Marinho FA, Sangenito LS, Oliveira SSC, Goncalves KC, Ennes-Vidal V, d‘Avila-Levy CM, Santos ALS. Calpains: potential targets for alternative chemotherapeutic intervention against human pathogenic Trypanosomatids. Curr Med Chem. 2013;20(25):3174–3185.
   PubMed Web of Science ®Google Scholar
• Studer G, Tauriello G, Bienert S, Biasini M, Johner N, Schwede T. ProMod3 – a versatile homology modelling toolbox. PLoS Comput Biol. 2021;17(1):e1008667.
   PubMed Web of Science ®Google Scholar
• Waterhouse A, Bertoni M, Bienert S, Studer G, Tauriello G, Gumienny R, Heer FT, de Beer TAP, Rempfer C, Bordoli L, et al. SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic Acids Res. 2018;46(W1):W296–W303.
   PubMed Web of Science ®Google Scholar
• Bienert S, Waterhouse A, de Beer TAP, Tauriello G, Studer G, Bordoli L, Schwede T. The SWISS-MODEL repository – new features and functionality. Nucleic Acids Res. 2017;45(D1):D313–D319.
   PubMed Web of Science ®Google Scholar